MOBERG DERMA AND MEDICAL FUTURES INC SIGNS COMMERCIAL AGREEMENT FOR NAIL PRODUCT IN CANADA
Moberg Derma AB, Sweden and Medical Futures Inc, Canada (“MFI”), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma’s novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the Canadian market. Financial terms include payments for product supply and milestones.
“Our joint goal is to build a significant franchise in the Canadian market for nail disease treatments. We are impressed with MFI’s approach and momentum and are excited about the prospects of our collaboration", says Moberg Derma's President and CEO, Peter Wolpert. Paul Johns, VP Sales and Marketing of Medical Futures Inc., says: "I am very pleased that we secured a collaboration with Moberg Derma, one of few companies bringing innovation in Dermatology. We identified Moberg’s new nail product as the most promising novel topical treatment alternative for nail fungus. This is a large disease area previously lacking good products. This latest addition to our portfolio has the potential to become an important growth driver for MFI" About the product and nail fungus Moberg’s topical nail product is prescription free and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. The product has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
Tags: